Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Tag: acute myeloid leukemia
A better roadmap for beating a deadly leukemia
Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a...
Overcoming drug resistance to stop a deadly blood cancer
Cancer researchers have discovered a potential way to make targeted therapy drugs more effective and longer lasting for people with acute myeloid leukemia, or AML. The scientists showed how it is...
Unraveling early events in a life-threatening leukemia
Cancer scientists reveal the first direct evidence that leukemia development depends on the order in which mutations occur. Acute myeloid leukemia, or AML, is the most common blood cancer in adults...
Study overturns basic tenet in leukemia biology
Scientists thought they understood the steps leading to acute myeloid leukemia. But one of the basic tenets in that understanding turns out to be unsound, according to researchers at the OHSU Knight...
How a deadly leukemia develops resistance to one of the newest targeted therapies
OHSU Knight Cancer Institute scientists have identified key gene networks and signaling pathways that cancerous cells in acute myeloid leukemia use to resist treatment with the drug venetoclax, one...
Studies reveal new ways to fight a deadly leukemia
One study shows how it may be possible to stop acute myeloid leukemia by targeting a hidden population of cells that support the cancer. Another reveals how AML evolves to evade anti-cancer drugs,...
Rapid precision medicine is feasible in fight against a formidable leukemia
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
An elaborate clinical trial aims a multitude of targeted therapies at one formidable cancer
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Fighting a formidable leukemia with an expansive clinical trial
The best available treatment for acute myeloid leukemia is a drug combination established more than 30 years ago. And today less than a third of newly diagnosed AML patients survive beyond five...
How a formidable leukemia subverts blood stem cells
New findings open a path for developing desperately needed therapies for the most frequently diagnosed leukemia in adults. Leukemia paves the way for its deadly advance by manipulating the...